Close this search box.

The Institute for Patient Access raised several concerns during ICER’s open input period. Based on the methodology described in the draft scoping document, however, it does not appear that ICER’s cost-effectiveness evaluation will adequately address these issues.

Read the Comments

Leave a Reply

Your email address will not be published. Required fields are marked *